[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-vessel-ischemic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-vessel-ischemic-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100630702","brazilian-prospective-registry-of-the-inspiron-evo-drug-eluting-stent-in-complex-coronary-lesions-100630702",false,"NCT07491107","Brazilian Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions","National Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions","PCI EVOlution","Inclusion Criteria:\n\n* Individuals aged 18 years or older presenting with complex coronary lesions requiring percutaneous coronary intervention (PCI).\n* Individuals who provide consent and are willing to comply with the follow-up protocol.\n* Individuals who received treatment with the Inspiron™ EVO Stent.\n* Individuals with lesions ≥ 30 mm in length (Subprotocol 1).\n* Individuals with significantly calcified coronary lesions (moderate to severe according to the ACC\u002FAHA classification B1, B2, or C), with or without indication for lesion preparation techniques (Subprotocol 2).\n* Individuals with multivessel coronary artery disease (≥2 affected coronary vessels, with at least one vessel of small diameter ≤2.5 mm) (Subprotocol 3).\n* Individuals included in Subprotocol 1, 2, or 3. The evaluated segment must be accessible to the IVUS (Intravascular Ultrasound) catheter (Subprotocol 4).\n\nExclusion Criteria:\n\n* Lesions in saphenous vein grafts or internal mammary grafts.\n* Contraindication to the use of a drug-eluting stent.\n* Individuals who were treated during the index procedure with any stent other than the Inspiron™ EVO Stent.","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","12 Months","OBSERVATIONAL","The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population. Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions will be treated with the Inspiron™ EVO drug-eluting stent.",[26,27,28,29,30,31],"Coronary Artery Disease (CAD)","Stenosis Coronary","Small Vessel Ischemic Disease","Multivessel Coronary Artery Disease","Calcific Coronary Arteriosclerosis","Complex Coronary Lesions","NOT_YET_RECRUITING","2026-03-24",{"date":35,"type":36},"2026-03-30","ACTUAL",{"date":38,"type":21},"2026-04-30",{"date":40,"type":21},"2030-04-30",{"name":42,"class":43},"Scitech Produtos Medicos SA","INDUSTRY"]